Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study
Abstract Background Expanded access programs (EAPs) allow patients with serious, life-threatening conditions access to drugs prior to their formal approval. Despite the possible benefits for patients, EAPs present several challenges, including uncertainty regarding a drug’s efficacy and safety as we...
Main Authors: | Petra Kiefer, Janbernd Kirschner, Astrid Pechmann, Thorsten Langer |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-020-01477-7 |
Similar Items
-
The efficacy and safety of nusinersen within the expanded access program in Russia
by: S. B. Artemieva, et al.
Published: (2020-12-01) -
Clinical experience of nusinersen in a broad spectrum of spinal muscular atrophy: A retrospective study
by: Ae Ryoung Kim, et al.
Published: (2020-01-01) -
Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
by: Praveen Thokala, et al.
Published: (2020-10-01) -
Posterior Spinal Correction and Fusion Surgery in Patients with Spinal Muscular Atrophy-Associated Scoliosis for Whom Treatment with Nusinersen Was Planned
by: Shuhei Machida, et al.
Published: (2021-03-01) -
Nusinersen in spinal muscular atrophy: Respiratory outcomes at tertiary care centers
by: Fahad Alsohime, et al.
Published: (2020-01-01)